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Abstract
Purpose There are known associations between treatment of prostate cancer (PCa) involving Androgen Deprivation Therapy 
(ADT) and psychological and physical side effects. We investigate the associations between cancer-related symptoms, health-
related quality of life (HRQL), and poor psychological outcomes in men whose treatment for PCa involved ADT.
Methods A cross-sectional postal questionnaire was administered to UK men 18–42 months post diagnosis of PCa. Men 
completed items on functional outcomes using the Expanded Prostate Cancer Index Composite (EPIC-26), EuroQol-5D 
(EQ-5D), and the European Organisation for Research and Treatment of Cancer (EORTC) Fatigue subscale. Psychological 
outcomes (mental well-being and psychological distress) were assessed using the Short Warwick–Edinburgh Mental Well-
being Scale (SWEMWBS) and the Kessler 6-item scale (K6), respectively. Associations between explanatory variables and 
psychological outcomes were assessed using stepped logistic regression.
Results 13,097 men treated with ADT completed a questionnaire. A minority of men reported poor mental well-being 
(15.5%) or severe psychological distress (6.6%). After controlling for sociodemographic and clinical variables, reporting 
clinically significant fatigue was strongly associated with severe psychological distress (OR 9.92; 95% CI 7.63 to 12.89) and 
poor well-being (OR 3.86; 95% CI 3.38 to 4.42). All cancer-related symptoms and HRQL variables were associated with 
both psychological outcomes.
Conclusions While the majority of men treated with ADT did not report poor psychological outcomes, a small proportion 
reported severe problems. Clinically significant fatigue was demonstrated as a possible indicator of poor outcomes. Health-
care systems need to have clear protocols in place which specifically and routinely target psychological distress and fatigue.
Keywords Prostate cancer · Psychological distress · Mental well-being · Androgen deprivation therapy · Cancer-related 
symptoms · Patient-reported outcome measures
Introduction
Prostate cancer (PCa) is the most common cancer in men 
in the UK [1]. Over the last 40 years, the number of men 
living with a diagnosis of PCa survival has tripled [2]. With 
increasing numbers living for long periods with and beyond 
their diagnosis, understanding and improving the experience 
of patients post diagnosis and treatment are growing priori-
ties [3]. The National Cancer Research Institute (NCRI) has 
identified the UK Top 10 Living With and Beyond Can-
cer research priorities, which includes understanding the 
short- and long-term psychological impacts of cancer [4, 
5]. One group that may be at greater risk of experiencing 
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the negative psychological impact of PCa is the increasingly 
prevalent group of men, particularly with earlier stage of 
disease, treated with Androgen Deprivation Therapy (ADT) 
[6, 7].
There are known associations between ADT and depres-
sion, memory difficulties, and fatigue among prostate cancer 
patients [8–11]. A recent meta-analysis of 18 studies found 
that risk of depression increased by 41% in men on ADT 
[12]. The largest study to date of 100,000 men with and 
without PCa [6] also supported this association; however, 
when controlling for age, comorbidity, and tumour charac-
teristics, this relationship was no longer significant. Further 
studies have shown that 19.6% of men on ADT report clini-
cally significant anxiety and that increasing ADT length is 
associated with poorer quality of life [13], and increased 
risk of anxiety [14].
Mental well-being is a broad concept, which has been 
described as the positive aspects of mental health [15]. Non-
specific psychological distress occurs in a range of mental 
health disorders, but is not specific to any one disorder [16]. 
It therefore provides an indicator of potential mental health 
problems. Previous studies of PCa have indicated the rela-
tionship between the severity of cancer-related symptoms 
experienced and poorer mental well-being and/or severe psy-
chological distress [17, 18]. However, little work has been 
done regarding the associations with cancer-related symp-
toms in patients receiving ADT despite its links to physical 
(vitality, energy, and fatigue) and sexual dysfunction. There 
is some suggestion that ADT may indirectly affect risk of 
psychological distress through an overall reduction in quality 
of life [19]. The use of Patient-Reported Outcome Measures 
(PROMs) in large surveys allows clinicians to generate more 
confident estimates of this kind and therefore allow the plan-
ning of appropriate clinical responses.
The Life After Prostate Cancer Diagnosis (LAPCD) study 
is a UK-wide, population-based, cross-sectional study inves-
tigating a range of quality of life (QoL) outcomes in men 
18–42 months post diagnosis of PCa. As part of the LAPCD 
study, Downing et al. [20] recently reported that later-stage 
PCa was associated with fatigue and sexual dysfunction and 
this was suggested to be due to receiving ADT. While previ-
ous studies have investigated cancer-related symptoms and 
psychological outcomes in PCa [17], no large-scale study 
has focused its attention on treatments involving ADT. 
Qualitative interviews conducted alongside the quantitative 
LAPCD survey have also supported ADT treatment as being 
related to changes in mood along with bodily changes, such 
as mood swings and loss of muscle mass, which were related 
to distress (Matheson et al. submitted).
Aim: As part of the LAPCD study, we aim to investigate 
which cancer-related symptoms and health-related quality of 
life (HRQL) variables are associated with mental well-being 
and psychological distress in men 18-42 months post diag-
nosis of PCa who reported receiving ADT.
Methods
The LAPCD study design has been detailed previously 
[21]. Men diagnosed with PCa between 18 and 42 months 
previously were identified through national cancer registra-
tion systems in England, Wales, and Northern Ireland, and 
through hospital activity data in Scotland. These men were 
sent a postal survey between October 2015 and November 
2016. The survey comprised validated PROMs covering 
generic, cancer, and PCa-specific outcome domains along-
side those addressing quality of life, and psychological 
and social outcomes. The full questionnaire is available in 
Online Resource 1.
Age was self-reported, and where missing, was supple-
mented by cancer registration records. Participants also 
self-reported employment status, ethnicity, legal marital 
status, sexuality, the presence of other long-term conditions 
(LTCs) from a list of co-morbidities (e.g. diabetes, heart 
disease), and carer status. Body Mass Index (BMI) was cal-
culated using self-reported height and weight. An area-based 
measure of socio-economic deprivation was derived from 
postcodes using the Index of Multiple Deprivation (IMD) 
[22–25]. Men were asked to report whether or not in the past 
they had ever in their lifetime seen a healthcare professional 
(e.g. GP, psychiatrist, psychologist, counsellor) for problems 
with emotions or nerves or use of alcohol or drugs (referred 
to from here on as history of help-seeking for mental health 
problems/alcohol/drugs). Cancer stage at time of diagno-
sis was provided by national cancer registries. Treatment 
received was self-reported. Men were split into those receiv-
ing ADT and those not receiving ADT based on whether 
they had indicated that they had received hormone treatment 
(alone or in combination with external beam radiotherapy 
[EBRT], surgery or other systemic treatment; see Online 
Resource 2). The duration of ADT use was not assessed.
Cancer‑related symptoms
The EuroQol-5D-5L (EQ-5D-5L) includes questions on 
five dimensions (mobility, self-care, usual activities, pain/
discomfort, and anxiety/depression). Each dimension item 
has five response options (e.g. “I have no problems walk-
ing about” up to “I am unable to walk about”). The EQ-5D 
also includes a rating of self-assessed health (SAH) based 
on “how good or bad your health is today”, ranked from 0 
to 100 where 100 represents best possible health. The pro-
portion of respondents reporting any problem, regardless 
of severity, in each dimension separately and across four 
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of the five dimensions was computed along with average 
SAH ratings.
The Expanded Prostate Cancer Index Composite (EPIC-
26) is a 26-item measure of function and associated bother 
over five domains (urinary incontinence, urinary irritation 
and obstruction, bowel, sexual, and hormonal function) [26]. 
Each domain includes a question relating to ‘bother’ (“how 
big a problem has your function been for you during the past 
4 weeks?” on a five-point scale: no/very small/small/moder-
ate/big problem). The proportion of respondents reporting 
moderate or big bother in each domain was computed [20]. 
Scoring for the EPIC-26 does not provide cut-offs to indicate 
clinical significance of symptoms.
The European Organisation for Research and Treatment 
of Cancer (EORTC)-Fatigue subscale includes three items: 
During the past week (Did you need to rest; have you felt 
weak; were you tired) scored between ‘not at all’ and ‘very 
much’, where a high score indicates more problems. A score 
greater than 39 is considered to indicate clinically significant 
fatigue [27].
Psychological outcome measures
The Short Warwick–Edinburgh Mental Well-being Scale 
(SWEMWBS) [28] is a seven-item measure of mental well-
being. Respondents complete items relating to their experi-
ences, thoughts, and feelings ‘over the past 2 weeks’. Scores 
range from 7 to 35 with higher scores indicating greater 
well-being. It is suggested that scores ≤ 19.25 indicate poor 
mental well-being [29].
The Kessler 6 (K6) is a validated measure of psycho-
logical distress which asks individuals to report their experi-
ences over the past 30 days and is assessed using a five-point 
Likert style scale, anchored between 5 (“All of the time”) 
and 1 (“None of the time”) [30, 31]. Using the Australian 
K6 scoring system, possible scores range between 6 and 30, 
where a score of 19–30 indicates severe psychological dis-
tress (and possible serious mental illness).
Only the first four dimensions of the EQ-5D and EPIC-26 
were included in these analyses due to a lack of independ-
ence between the anxiety/depression dimension and hormo-
nal function and both outcome measures.
Analysis summary
Analyses were limited to men that self-reported receiving 
ADT either alone or in combination with other treatments.
Missing data were imputed in order to reduce potential 
bias associated with only including cases with complete data 
[32, 33]. Multiple imputation with chained equations was 
utilised [34] based upon all sociodemographic and clinical 
characteristics and all bother and HRQL items, along with 
the EORTC-fatigue subscale and both outcomes (severe 
psychological distress and poor mental well-being). Ten 
separate imputations were completed [34], with results 
combined using Rubin’s rules [35]. All respondents were 
therefore included in analyses. A secondary complete case 
analysis without multiple imputation was also conducted 
(Online Resources 3, 4).
The pre-defined cut-offs for SWEMWBS (≤ 19.25) 
and K6 (> 19) were used as binary outcomes to indicate 
poor mental well-being and severe psychological distress, 
respectively.
Stepped-regression analyses were conducted as follows:
1. Descriptive statistics Chi-squared analyses were con-
ducted to assess relationships between sociodemo-
graphic and clinical background variables and SWEM-
WBS/K6.
2. Core model development Multivariable analyses on 
each outcome (SWEMWBS and K6) were performed 
entering all sociodemographic and clinical background 
variables (Age, LTCs, Employment, Ethnicity, Marital 
status, Deprivation, Carer status, Mental health help-
seeking, BMI, Nation, and Stage as explanatory vari-
ables). Those that were significant in this analysis were 
classified as the ‘core’ models (see Table 2 for the list of 
variables included in core models). To avoid dropping 
variables which might be borderline significant follow-
ing the addition of the variables in step 3, a significance 
level of 0.25 was used, any variables above this were 
dropped from the core model.
3. Final models Each cancer-related symptom (binary 
bother for urinary incontinence, urinary irritation, bowel 
function, sexual function, and fatigue (no clinical fatigue 
vs. clinical fatigue), continuous EQ-5D SAH, and binary 
no problems vs. some problems with mobility, self-care, 
usual activities, and pain/discomfort) was then entered 
individually into separate multivariable analyses in addi-
tion to the ‘core’ models. This was performed on the two 
outcomes separately. All cancer-related symptoms were 
a priori selected for inclusion within the final models.
Results
Descriptive statistics
In the overall LAPCD sample, 35,823 men responded to 
the questionnaire (60.8% response rate) of whom 30,114 
men reported receiving one of the most common treat-
ment types (Online Resource 2). 13,097 (43.5%) men 
reported receiving ADT. These men were older (Mean 
age = 73.49, SD = 7.38) than the men who did not have ADT 
(Mean = 69.7, SD = 7.92, p < .001). In the group treated with 
ADT, most men (89.3%; N = 11,696) were aged 65 + and 
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40.9% (N = 5354) reported having two or more other LTCs 
(Table 1). Table 1 also shows the levels of missing data by 
each characteristic, prior to multiple imputation.
Of the men receiving ADT, the majority of men reported 
receiving both EBRT and ADT (N = 7488; 57.2%), or 
ADT alone (N = 3116, 23.8%). Smaller proportions of 
men reported receiving ADT with both surgery and EBRT 
(N = 901, 6.9%), with surgery (N = 581, 4.4%), and with 
other systemic treatments (N = 1011, 8.1%; Table 1). Men 
treated with ADT alone were older (20.6% in men aged 
85 + vs. 1.1% of EBRT and ADT) and were more likely to 
have metastatic disease than men treated with combined 
ADT and EBRT (43.5% stage IV disease vs. 9.8%; Online 
Resource 6).
Cancer‑related symptoms
Just under 40% of the ADT-treated men reported clini-
cally significant fatigue on the EORTC subscale (38.6%, 
N = 4619). On the EQ-5D, just under half of men reported 
some problems with pain/discomfort (N = 6203, 47.9%), 
mobility (N = 5687, 43.9%) and usual activities (N = 5980, 
46.1%). The average SAH score for men treated with ADT 
was 74.0 (SD = 18.6).
On the EPIC-26, just under half of men on ADT reported 
moderate/big problems in sexual functioning (45.3%, 
N = 5426). Smaller proportions of the men reported moder-
ate or big problems with urinary (13.5%, N = 1744) or bowel 
function (11.5%, N = 1491).
Psychological outcomes
12,275 (93.5%) men completed the SWEMWBS. 1908 
(15.5%) scored below the SWEMWBS cut-off to indicate 
poor mental well-being. 12,507 completed the K6 (95.4% 
complete), 826 men (6.6%) scored below the K6 cut-off indi-
cating severe psychological distress (Table 1).
Sociodemographic and clinical variable analyses 
(core models; Table 2)
Scoring below the cut-off for well-being was associated with 
unemployment at the time of survey, having a greater num-
ber of LTCs, living in an area of greater deprivation, hav-
ing previously visited a healthcare professional for mental 
health-related problems, and marital status (being separated/
divorced).
Scoring below the cut-off for distress was associated with 
the same variables as for well-being, with a few exceptions. 
Nation and age were significant in the distress model but not 
the well-being model, and marital status was significant in 
the well-being model but not the distress model (Table 2).
Table 1  Characteristics of men treated with ADT included in analysis 
before multiple imputation (numbers and percentages)
Characteristics N % Missing (%)
Total 13,097 100.0
Age group, years
 < 55  89 0.7 3 (0.01%)
 55–64  1309 10.0
 65–74  5696 43.5
 75–84  5128 39.2
 85 + 872 6.7
Number of LTCs
 0 3192 24.4 0
 1 4551 34.8
 2 2867 21.9
 3 1413 10.8
 4+ 1074 8.2
Stage
 I/II 5276 46.2 1667 (12.7)
 III 3441 30.1
 IV 2713 23.7
Employment
 Employed 1729 13.6 362 (2.8)
 Unemployed 275 2.2
 Retired 10,679 83.9
 Other 52 0.4
Ethnicity
 White 12,501 98.9 335 (2.6)
 Non-white 261 2.1
Marital/relationship status
 Married/civil partner 10,321 79.6 126 (1.0)
 Separated/divorced 882 6.8
 Widowed 1142 8.8
 Single 471 3.6
 Other 155 1.2
Deprivation
 1 least deprived 3450 27.0 307 (2.3)
 2 3471 27.1
 3 2785 21.8
 4 1889 14.8
 5 most deprived 1195 9.3
Carer status
 No 9536 75.6 486 (3.7)
 Yes 3075 24.4
Mental health help-seeking
 No 10,643 83.4 328 (2.5)
 Yes 2126 16.7
BMI
 Under/healthy weight (0–25) 3398 28.1 1015 (7.7)
 Overweight (25–30) 5749 47.6
 Obese (30+) 2935 24.3
Nation
 England 11,116 84.9 0
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Cancer‑related symptoms (final models; Table 3)
The final multivariable models included all of the significant 
sociodemographic and clinical variables from the core mod-
els. Each of the cancer-related symptoms from the EPIC-26 
and HRQL from the EQ-5D along with the EORTC-fatigue 
binary variable were individually analysed while controlling 
for the variables in the core model.
The variable most strongly associated with poor mental 
well-being was reporting problems with self-care (OR 3.89; 
95% CI 3.39 to 4.48), followed by reporting clinical levels of 
fatigue (OR 3.86; 3.38 to 4.42), problems with usual activi-
ties (OR 3.37; 95% CI 2.94 to 3.86), and mobility (OR 2.81; 
95% CI 2.46 to 3.21). All cancer-related symptom bother 
and HRQL variables were significantly associated with psy-
chological distress and poor mental well-being.
In the distress model, the strongest association was with 
reporting clinically significant fatigue (OR 9.92; 95% CI 
7.63 to 12.89). Reporting problems with usual activities (OR 
6.42; 95% CI 5.00 to 8.24), mobility (OR 4.51; 95% CI 3.61 
to 5.63), and bother associated with bowel function (OR 
3.46; 95% CI 2.83 to 4.23) were all associated with distress.
Results using multiple imputation were comparable to 
complete case analysis (Online Resources 3, 5).
Discussion
This large study of just over 13,000 men diagnosed with 
prostate cancer who reported receiving ADT either alone or 
combined with other treatment, included men with all stages 
of disease at diagnosis. To our knowledge, this is one of 
the largest patient-reported outcome studies of men treated 
with ADT and therefore provides further insight into the 
relationship between cancer-related symptoms and psycho-
logical outcomes. As a population-based sample, not limited 
by stage of disease or specific ADT treatment, it therefore 
provides a general picture of psychological outcomes, using 
validated measures in men treated with ADT. The results 
demonstrate that while most men did not report poor psy-
chological outcomes 18–42 months post diagnosis, a small 
percentage of men reported poor mental well-being (15.5%) 
or severe psychological distress (6.6%). After controlling for 
sociodemographic and clinical variables, all cancer-related 
symptoms and HRQL were significantly associated with 
both poor mental well-being and psychological distress. 
Reporting clinically significant levels of fatigue was most 
strongly associated with psychological distress and was also 
strongly associated with poor mental well-being compared 
to men without this level of fatigue.
The findings therefore suggest that experiencing high lev-
els of fatigue is a possible indicator of poor mental health. 
However, at present, prostate cancer follow-up consultations 
are often focused on cancer-specific symptoms such as uri-
nary and bowel function. Fatigue and/or distress can there-
fore be overlooked and not directly enquired about, despite 
their prevalence in cancer patients, particularly in men from 
high-risk groups such as men treated with ADT [36]. Men 
LTCs long-term conditions, SAH self-assessed health
Table 1  (continued)
Characteristics N % Missing (%)
Total 13,097 100.0
 Wales 949 7.3
 Scotland 663 5.1
 NI 369 2.8
Treatment
 Androgen deprivation therapy (ADT) 
alone
3116 23.8
 EBRT + ADT 7488 57.2 0
 Surgery + EBRT & ADT 901 6.9
 Surgery + ADT 581 4.4
 Systemic therapy + ADT (+/EBRT) 1011 7.7
Mobility
 No problem 7280 56.1 130 (1.0)
 Some problems 5687 43.9
Self-care
 No problem 10,707 82.4 101 (0.8)
 Some problems 2289 18.0
Usual activities
 No problem 6990 53.9 127 (1.0)
 Some problems 5980 46.1
Pain/discomfort
 No problem 6740 52.1 154 (1.2)
 Some problems 6203 47.9
Urinary bother
 No bother 11,193 86.5 160 (1.2)
 Moderate/big bother 1744 13.5
Bowel bother
 No bother 11,499 88.5 107 (0.8)
 Moderate/big bother 1491 11.5
Sexual bother
 No bother 6541 54.7 1130 (8.6)
 Moderate/big bother 5426 45.3
Fatigue
 No fatigue 7353 61.4 1125 (8.6)
 Fatigue 4619 38.6
 SAH (mean, SD) 74 18.6
Mental well-being
 Well-being 10,367 84.5 822 (6.3)
 Poor mental well-being 1908 15.5
Psychological distress
 No/mild distress 11,681 93.4 590 (4.5)
 Severe psychological distress 826 6.6
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Table 2  Univariable and multivariable (core models) associations between sociodemographic and clinical factors and psychological distress and 
mental well-being
Characteristic Poor mental well-being Severe psychological distress
Univariable Multivariable (core model) Univariable Multivariable (core model)
OR (95% CI) OR (95% CI)
Age, years
 < 55  1.00 1.00 1.00 1.00
 55–64 1.29 (0.74–2.26) 1.16 (0.64–2.12) 0.79 (0.43–1.42) 0.60 (0.30–1.20)
 65–74 0.70 (0.40–1.20) 0.86 (0.47–1.57) 0.36 (0.20–0.64) 0.37 (0.18–0.73)
 75–84 0.85 (0.49–1.47) 1.10 (0.60–2.04) 0.31 (0.17–0.55) 0.33 (0.16–0.67)
 85+ 1.25 (0.71–2.19) 1.54 (0.82–2.90) 0.48 (0.26–0.91) 0.53 (0.25–1.13)
Number of LTCs
 0 1.00 1.00 1.00 1.00
 1 1.12 (0.97–1.29) 1.07 (0.92–1.23) 1.21 (0.95–1.55) 1.13 (0.88–1.45)
 2 1.63 (1.41–1.90) 1.49 (1.28–1.74) 2.12 (1.66–2.70) 1.90 (1.47–2.45)
 3 2.25 (1.89–2.66) 2.00 (1.68–2.39) 3.15 (2.43–4.08) 2.74 (2.08–3.60)
 4+ 3.06 (2.57–3.65) 2.57 (2.13–3.10) 5.93 (4.64–7.58) 4.88 (3.76–6.33)
Employment
 Employed 1.00 1.00 1.00 1.00
 Unemployed 5.56 (4.20–7.36) 3.34 (2.47–4.51) 9.10 (6.53–12.68) 4.37 (3.02–6.34)
 Retired 1.19 (1.03–1.39) 1.10 (0.92–1.31) 1.29 (1.02–1.63) 1.49 (1.12–1.97)
 Other 3.16 (1.74–5.75) 2.61 (1.40–4.87) 2.36 (0.91–6.12) 1.86 (0.67–5.12)
Ethnicity
 White 1.00 – 1.00 –
 Non-white 1.23 (0.89–1.71) 1.80 (1.20–2.69)
Marital status
 Married/civil partner 1.00 1.00 1.00 –
 Separated/divorced 1.69 (1.43–201) 1.38 (1.15–1.67) 1.97 (1.57–2.47)
 Widowed 1.56 (1.33–1.83) 1.38 (1.16–1.64) 1.24 (0.98–1.58)
 Single 1.53 (1.19–1.95) 1.26 (0.97–1.63) 1.19 (0.82–1.73)
 Other 1.47 (0.97–2.87) 1.25 (0.81–1.93) 1.66 (0.96–2.86)
Deprivation quintile
 1 least deprived 1.00 1.00 1.00 1.00
 2 1.20 (1.04–1.39) 1.18 (1.01–1.37) 1.24 (0.99–1.55) 1.19 (0.95–1.49)
 3 1.25 (1.07–1.45) 1.16 (0.99–1.35) 1.54 (1.24–1.93) 1.39 (1.10–1.75)
 4 1.67 (1.42–2.96) 1.45 (1.22–1.71) 2.44 (1.95–3.06) 1.94 (1.53–2.46)
 5 most deprived 2.38 (1.98–2.87) 1.87 (1.53–2.28) 3.38 (2.67–4.28) 2.29 (1.77–2.96)
Carer status
 No 1.00 – 1.00 –
 Yes 1.07 (0.95–1.20) 1.11 (0.94–1.30)
Mental health help-seeking
 No 1.00 1.00 1.00 1.00
 Yes 2.39 (2.13–2.68) 2.17 (1.92–2.46) 3.81 (3.27–4.43) 3.13 (2.66–3.69)
Stage
 I/II 1.00 1.00 1.00 1.00
 III 1.04 (0.92–1.18) 1.06 (0.93–1.21) 1.14 (0.95–1.37) 1.18 (0.97–1.43)
 IV 1.21 (1.06–1.38) 1.22 (1.07–1.40) 1.25 (1.04–1.49) 1.26 (1.04–1.53)
BMI
 < 25 under/healthy 1.00 1.00 1.00 1.00
 25–30 overweight 0.86 (0.76–0.98) 0.86 (0.75–0.99) 0.95 (0.79–1.15) 0.90 (0.74–1.10)
 30+ obese 1.30 (1.14–1.48) 1.16 (1.00–1.33) 1.70 (1.39–2.08) 1.27 (1.02–1.57)
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treated with ADT may be particularly vulnerable to poor 
psychological outcomes during and following treatment, 
yet may struggle to raise the issue of their mental health 
during clinical encounters. Men may also have difficulty in 
discussing the side effects of treatment, particularly due to 
the sensitive nature of the bodily changes that occur as part 
of ADT treatment (Matheson et al. submitted).
The men treated with ADT were compared to those 
treated without ADT (Online Resource 7). Cancer-related 
symptoms were reported by a greater proportion of the men 
treated with ADT, in particular, fatigue levels which are con-
sistent with existing literature [6]. The levels of distress and 
poor well-being reported were also significantly higher in 
the group treated with ADT. These results support the focus 
of this study being on these particularly vulnerable men.
The development of the K6 included cross-validation 
with other measures of mental illness and assessment of 
its applicability as a screening tool [28, 29]. Although the 
K6 is not a diagnostic tool, the cut-off used in this study 
has been demonstrated as an indicator of possible severe 
mental illness [37]. The finding that a minority of men 
treated with ADT reported poor psychological outcomes 
is consistent with the literature, although the proportions 
reporting psychological distress were smaller than previous 
reports of anxiety [13]. This may be a consequence of the 
18–42-month post-diagnosis timeframe used in the present 
study. The study findings demonstrate that a small propor-
tion of men treated with ADT reported experiencing both 
clinically significant levels of fatigue as indicated by the 
EORTC-fatigue subscale, along with clinically significant 
psychological distress. This highlights the potentially unmet 
needs in these men.
The results from the present study support the routine 
use of tools to assess fatigue and/or psychological distress 
in clinical consultations or health needs assessments, which 
could help prompt earlier referral for intervention to help 
with the experience of cancer-related fatigue (e.g. super-
vised exercise, clinical psychology input, anti-depressants) 
[38–40]. These findings are particularly timely as over the 
past year, treatment for locally advanced and metastatic 
prostate cancer with ADT has become more intensive [41]. 
Chemotherapy is now used up front with ADT and the rou-
tine use of radiotherapy in men with limited metastatic dis-
ease may become a standard of care following recent data 
from the UK MRC STAMPEDE trial [42, 43].
The results would support incorporating specific advice 
on managing fatigue and risks of poor psychological out-
comes in men treated with ADT into the education and 
supported self-management events that are currently being 
implemented as part of the recovery and rehabilitation pro-
grammes. Although many men treated with radiotherapy 
and ADT receive only short-term hormone deprivation 
therapy (circa 6 months), it can take 12–24 months before 
any related symptoms resolve and up to 10% may remain 
castrate with on-going problems [44, 45]. Often men with 
prostate cancer (and their health teams) are unaware of the 
risk of the continuing symptoms despite stopping ADT [46].
Strengths and limitations
Reported here is a large-scale study of men diagnosed with 
prostate cancer and administered with ADT, not restricted 
by age or stage, representing one of the largest samples of 
men diagnosed with prostate cancer on ADT and providing 
N = 13,097
Models based on imputed data
An OR greater than 1 represents greater odds than the first group listed (reference category) of reporting psychological distress or poor mental 
well-being
A dash (–) indicates that the variable was not significant in the multivariable analysis and was not included in the core model
The distress core model included: Age, Number of LTCs, Employment, Deprivation, having visited a healthcare professional for mental health/
alcohol/drug related problems, BMI, nation, and stage at diagnosis. The mental well-being core model included: number of LTCs, Employment, 
Marital status, Deprivation, having visited a healthcare professional for mental health/alcohol/drug related problems, BMI, and stage at diagnosis
OR odds ratio, CI confidence interval
Table 2  (continued)
Characteristic Poor mental well-being Severe psychological distress
Univariable Multivariable (core model) Univariable Multivariable (core model)
OR (95% CI) OR (95% CI)
Nation
 England 1.00 – 1.00 1.00
 Wales 1.19 (0.99–1.42) 1.36 (1.07–1.73) 1.32 (1.02–1.71)
 Scotland 1.25 (1.01–1.54) 1.38 (1.04–1.84) 1.28 (0.95–1.73)
 NI 1.08 (0.80–1.45) 1.34 (0.92–1.97) 1.13 (0.74–1.72)
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important new data to better understand the experiences 
of these men. Validated measures of mental well-being 
and psychological distress were used to investigate these 
outcomes at 18–42 months post diagnosis. Additionally, 
the questionnaire response rate was 61%, which is typical 
for health-related surveys of this kind [47].
A key limitation of the present study is the cross-sectional 
nature of the data which means that causation cannot be 
inferred. The data also refer to a single time-point follow-
ing diagnosis and treatment, which limits our understand-
ing of the men’s experience over time. There was a lack of 
a baseline measure of either mental well-being or distress; 
Table 3  Multivariable 
associations between cancer-
related symptoms, HRQL 
and psychological distress 
and mental well-being among 
prostate cancer survivors who 
received ADT, after controlling 
for variables in the core models
N = 13,097
Models based on imputed data
The ORs were estimated using separate logistic regression models, controlling for the variables in the core 
models
SAH Self-assessed health. This was a continuous variable scored out of a total of 100 where a greater 
score indicates better HRQL. An odds ratio of less than 1 for this variable can be interpreted to mean that 
a decrease in self-reported health was associated with both psychological distress and poor mental well-
being (each 1 point reduction in SAH was associated with odds of 1.05 for reporting psychological distress/
poor well-being)
OR odds ratio, CI confidence interval
a The mental well-being core model included: number of LTCs, Employment, Marital status, Deprivation, 
having visited a healthcare professional for mental health/alcohol/drug-related problems, BMI, and stage at 
diagnosis
b The distress core model included: Age, Number of LTCs, Employment, Deprivation, having visited a 
healthcare professional for mental health/alcohol/drug-related problems, BMI, nation, and stage at diagno-
sis
c An odds ratio greater than 1 represents a greater odds than the first group listed (reference category) of 
reporting psychological distress or poor mental well-being
Symptoms and HRQL Poor mental well-beinga Severe psychological  distressb
OR (95% CI) OR (95% CI)
Urinary bother
 No bother 1.00 1.00
 Moderate/big bother 2.89 (2.54–3.27)c 3.69 (3.12–4.38)
Bowel bother
 No bother 1.00 1.00
 Moderate/big bother 2.50 (2.20–2.85) 3.68 (3.11–4.34)
Sexual bother
 No bother 1.00 1.00
 Moderate/big bother 1.75 (1.57–1.95) 2.71 (2.29–3.22)
Fatigue
 No fatigue 1.00 1.00
 Fatigue 3.77 (3.34–4.25) 9.71 (7.73–12.19)
Mobility
 No problems 1.00 1.00
 Some problems 2.98 (2.66–3.33) 4.63 (3.82–5.63)
Self-care
 No problems 1.00 1.00
 Some problems 3.98 (3.54–4.47) 6.45 (5.41–7.69)
Usual activities
 No problems 1.00 1.00
 Some problems 3.49 (3.09–3.94) 6.53 (5.26–8.11)
Pain/discomfort
 No problems 1.00 1.00
 Some problems 2.33 (2.09–2.60) 3.74 (3.07–4.53)
SAH .95 (.95–.96) .94 (.94–.95)
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although we did ask about previous mental health/alcohol-
related contact with health services. It is, therefore, not 
possible to know precisely the progression of well-being/
distress after treatment, or whether these were present before 
the start of treatment. It was also beyond the scope of this 
research to collect general population comparison data 
from across the UK and we only know the outcomes of the 
responding men. These factors limit the interpretation of 
the results to an extent, and caution should be taken when 
generalising the findings as longitudinal data are needed 
to confirm the findings. However, as a result of the 61% 
response rate and the large sample size, the present findings 
remain the largest of their kind and add to our understanding 
of these outcomes in men treated with ADT.
The time period of 18–42 months was selected as it repre-
sents the period when initial treatment is complete and side 
effects and quality of life have begun to stabilise. However, 
the survey did not collect data on the specific time since 
diagnosis of each respondent, and this is a limitation of the 
study. While the relationship between increased duration of 
ADT treatment and poorer quality of life is known [48], we 
did not know the duration of ADT treatment or whether the 
men were still in receipt of ADT at the time of the survey 
[13]. There is therefore likely variability in the respondents’ 
experiences of receiving ADT, both in duration and dose, 
which was not able to be controlled for in the multivariable 
analyses. In addition to this, the specific type of combination 
treatment was not included as an explanatory variable, due to 
the small size of a number of these subgroups. Due to this, 
we are not able to provide further insight as to whether cer-
tain treatment groupings had greater association with poor 
psychological outcomes.
There are a number of avenues for future research based 
on these findings. Further research is needed to study ways 
of dealing with the adverse effects of ADT. As mentioned 
previously, there is some evidence for physical activity inter-
ventions in reducing fatigue [38, 39, 49] although the impact 
of physical activity on outcomes in men with prostate cancer 
is incompletely understood, particularly in relation to mental 
health. Further high-level research is needed, in part this is 
currently being tested in a formal randomised trial setting in 
the UK (the ‘STAMINA’ study [50]), but results will not be 
available for some time. Mechanistically, physical activity 
might be expected to ameliorate the cardiovascular adverse 
effects of ADT, just as it does in other settings such as dia-
betes or established cardiovascular disease.
Conclusions
While most men treated with ADT living 18–42 months fol-
lowing a diagnosis of PCa do not report poor mental well-
being or severe psychological distress, a small proportion 
report poor psychological outcomes. Reporting clinically 
significant levels of fatigue was found to be a clear indica-
tor of psychological distress. These results support the need 
to enquire about fatigue and distress more directly as part 
of the clinical interaction [51] and for healthcare systems to 
have clear protocols in place which specifically and routinely 
target both psychological distress and fatigue.
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